Immune cell combo shows promise in tough lung cancer
Disease control
Completed
This early-stage study tested whether adding PB101 (a patient's own natural killer cells) to standard targeted therapy is safe for people with advanced EGFR-mutated non-small cell lung cancer. Eight adults with stage IIIB/IV disease received the combination. The main goal was to …
Phase: PHASE1 • Sponsor: Precision Biotech Taiwan Corp. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC